Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Concert Pharmaceuticals Inc    CNCE

CONCERT PHARMACEUTICALS INC (CNCE)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
19.96(c) 20.26(c) 21.33(c) 21.51(c) 21.48(c) Last
263 848 218 166 223 281 362 714 150 930 Volume
-0.65% +1.50% +5.28% +0.84% -0.14% Change
More quotes
Financials ($)
Sales 2017 149 M
EBIT 2017 96,7 M
Net income 2017 94,2 M
Finance 2017 169 M
Yield 2017 -
Sales 2018 0,11 M
EBIT 2018 -61,9 M
Net income 2018 -61,3 M
Finance 2018 93,7 M
Yield 2018 -
P/E ratio 2017 5,37
P/E ratio 2018
EV / Sales2017 2,15x
EV / Sales2018 3 601x
Capitalization 490 M
More Financials
Company
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology.Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system... 
More about the company
Surperformance© ratings of Concert Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on CONCERT PHARMACEUTICALS IN
02/14CONCERT PHARMACEUTICALS : Announces Initiation of Enrollment in Second Cohort of..
AQ
02/12CONCERT PHARMACEUTICALS : Announces Initiation of Enrollment in Second Cohort of..
BU
01/19CONCERT PHARMACEUTICALS : Announces Patent Trial and Appeal Board Did Not Instit..
AQ
01/19CONCERT PHARMACEUTICALS : FDA Grants Fast Track Designation to Concert Pharmaceu..
AQ
01/15CONCERT PHARMACEUTICALS : FDA Grants Fast Track Designation to Concert Pharmaceu..
AQ
01/15CONCERT PHARMACEUTICALS : Announces Patent Trial and Appeal Board Did Not Instit..
AQ
01/15CONCERT PHARMACEUTICALS INC : Today’s Research Reports on Stocks to Watch: Conce..
AC
01/13CONCERT PHARMACEUTICALS : Incyte prevails in patent challenge for blockbuster dr..
AQ
01/12CONCERT PHARMACEUTICALS : FDA Grants Fast Track Designation to Concert Pharmaceu..
PU
01/12CONCERT PHARMACEUTICALS : FDA Grants Fast Track Designation to Concert Pharmaceu..
BU
More news
Sector news : Biotechnology & Medical Research - NEC
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02/14Analyzing Concert Pharmaceuticals $CNCE and Blueprint Medicines $BPMC  
02/14Zacks Investment Research Upgrades Concert Pharmaceuticals $CNCE to “Hold”  
02/13In celebration of America Saves Week later this month, our very own Ryan Lync.. 
02/13Concert Pharma Receives a Hold from Mizuho Securities $CNCE  
02/13Concert Pharmaceuticals Inc $CNCE Expected to Post Quarterly Sales of $8.11 M.. 
More tweets
Qtime:119
News from SeekingAlpha
02/14ROTY EDITION 1 VOLUME 79 : Limited Downside Catalysts Vs. Binary Risk 
02/14CONCERT PHARMACEUTICALS : Expecting Upside From Here 
02/14YOUR DAILY PHARMA SCOOP : Akebia Update, Rexahn Data, Concert Commences Enrollme.. 
02/12Concert Pharma advancing mid-stage study of CTP-543 in autoimmune hair loss d.. 
02/06ROTY EDITION 1 VOLUME 76 : How To Deal With Market Selloffs And Spring Cleaning .. 
Chart CONCERT PHARMACEUTICALS IN
Duration : Period :
Concert Pharmaceuticals In Technical Analysis Chart | CNCE | US2060221056 | 4-Traders
Technical analysis trends CONCERT PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 25,6 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Roger D. Tung President, Chief Executive Officer & Director
Richard H. Aldrich Chairman
Nancy Stuart Chief Operating Officer
Marc Becker Chief Financial Officer
Wilfred E. Jaeger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CONCERT PHARMACEUTICALS INC-17.55%486
CELLTRION, INC.--.--%36 110
IQVIA HOLDINGS INC6.93%21 125
LONZA GROUP-7.82%18 606
INCYTE CORPORATION-6.91%18 063
NEKTAR THERAPEUTICS40.66%13 227